Stock Scorecard



Stock Summary for Lilly(Eli) & Company (LLY) - $819.85 as of 10/3/2025 3:05:41 PM EST

Total Score

10 out of 30

Safety Score

65 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LLY

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LLY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LLY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LLY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LLY (65 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 2
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LLY

Eli Lilly ( LLY ) Laps the Stock Market: Here's Why 10/3/2025 9:45:00 PM
5 Large Cap Drug Stocks: Values or Traps? 10/3/2025 8:55:00 PM
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets - Pfizer ( NYSE:PFE ) 10/3/2025 8:15:00 PM
Why Shares of Eli Lilly Soared This Week 10/3/2025 2:47:00 PM
MRK Stock Up Nearly 14% So Far This Week: What's Driving It? 10/3/2025 2:06:00 PM
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity - Eli Lilly ( NYSE:LLY ) 10/3/2025 2:02:00 PM
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump? 10/3/2025 1:59:00 PM
3 Blue Chip Stocks That Have Soared 380% ( and Higher ) Over the Past 5 Years 10/2/2025 9:27:00 AM
Eli Lilly Shares Are Trading Higher Wednesday: What's Going On? - Eli Lilly ( NYSE:LLY ) 10/1/2025 6:58:00 PM
Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away - CVS Health ( NYSE:CVS ) , Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE ) , UnitedHealth Group ( NYSE:UNH ) 10/1/2025 2:49:00 PM

Financial Details for LLY

Company Overview

Ticker LLY
Company Name Lilly(Eli) & Company
Country USA
Description Eli Lilly and Company (Ticker: LLY) is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana, and operating offices in 18 countries. With a broad portfolio of innovative medicines across key therapeutic areas, including diabetes, oncology, and neurodegenerative diseases, Lilly's products are sold in approximately 125 countries worldwide. The company is committed to advancing scientific innovation and improving patient outcomes through research and development, positioning itself as a pivotal player in addressing complex healthcare challenges. As a market leader, Eli Lilly continues to focus on sustainable growth strategies while enhancing shareholder value through its robust pipeline and strategic partnerships.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 6/30/2025
Next Earnings Date 10/30/2025

Stock Price History

Last Day Price 819.85
Price 4 Years Ago 266.55
Last Day Price Updated 10/3/2025 3:05:41 PM EST
Last Day Volume 5,066,023
Average Daily Volume 3,821,588
52-Week High 931.67
52-Week Low 622.41
Last Price to 52 Week Low 31.72%

Valuation Measures

Trailing PE 54.79
Industry PE 26.58
Sector PE 41.81
5-Year Average PE 61.21
Free Cash Flow Ratio 217.47
Industry Free Cash Flow Ratio 38.57
Sector Free Cash Flow Ratio 30.43
Current Ratio Most Recent Quarter 1.28
Total Cash Per Share 3.77
Book Value Per Share Most Recent Quarter 20.38
Price to Book Ratio 40.22
Industry Price to Book Ratio 10.68
Sector Price to Book Ratio 32.30
Price to Sales Ratio Twelve Trailing Months 14.14
Industry Price to Sales Ratio Twelve Trailing Months 3.95
Sector Price to Sales Ratio Twelve Trailing Months 20.26
Analyst Buy Ratings 15
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 896,457,000
Market Capitalization 734,960,271,450
Institutional Ownership 83.81%

Dividends

Ex-Dividend Date 8/15/2025
Previous Dividend Amount 1.5000
Current Dividend Amount 1.5000
Total Years Dividend Increasing Dividend Contender - Increasing for 10 Years
Trailing Annual Dividend Rate 5.80
Trailing Annual Dividend Yield 0.71%
Forward Annual Dividend Rate 6.00
Forward Annual Dividend Yield 0.73%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 0.68%
5-Year Average Dividend Yield 0.96%
1-Year Dividend Growth Rate Percentage 15.38%
3-Year Dividend Growth Rate Percentage 7.42%
5-Year Dividend Growth Rate Percentage 15.26%
All-Time Dividend Growth Rate Percentage 8.61%
Dividend Payout Ratio 37.83%

Income Statement

Quarterly Earnings Growth YOY 91.80%
Annual Earnings Growth 102.08%
Reported EPS 12 Trailing Months 15.33
Reported EPS Past Year 9.65
Reported EPS Prior Year 13.00
Net Income Twelve Trailing Months 13,799,900,000
Net Income Past Year 10,590,000,000
Net Income Prior Year 5,240,400,000
Quarterly Revenue Growth YOY 37.60%
5-Year Revenue Growth 15.08%
Operating Margin Twelve Trailing Months 45.80%

Balance Sheet

Total Cash Most Recent Quarter 3,375,900,000
Total Cash Past Year 3,268,400,000
Total Cash Prior Year 2,818,600,000
Net Cash Position Most Recent Quarter -30,804,200,000
Net Cash Position Past Year -25,258,700,000
Long Term Debt Past Year 28,527,100,000
Long Term Debt Prior Year 18,320,800,000
Total Debt Most Recent Quarter 34,180,100,000
Equity to Debt Ratio Past Year 0.33
Equity to Debt Ratio Most Recent Quarter 0.35
Total Stockholder Equity Past Year 14,192,100,000
Total Stockholder Equity Prior Year 10,771,900,000
Total Stockholder Equity Most Recent Quarter 18,272,900,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -50,200,000
Free Cash Flow Per Share Twelve Trailing Months -0.06
Free Cash Flow Past Year 414,300,000
Free Cash Flow Prior Year -3,152,000,000

Options

Put/Call Ratio 0.28
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.46
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 10/4/2025 3:34:41 AM EST